XSHG
600535
Market cap3.24bUSD
Dec 05, Last price
15.35CNY
1D
0.20%
1Q
-6.40%
Jan 2017
-48.20%
IPO
499.67%
Name
Tasly Pharmaceutical Group Co Ltd
Chart & Performance
P/E
24.00
P/S
2.70
EPS
0.64
Div Yield, %
3.84%
Shrs. gr., 5y
-0.20%
Rev. gr., 5y
-14.86%
Revenues
8.50b
-2.03%
Net income
956m
-10.78%
CFO
2.01b
-21.78%
Dividend
Oct 10, 20240.26 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tasly Pharmaceutical Group Co., Ltd. engages in biological medicine, health, and medical service businesses in China. It offers herbal and chemical medicines, health products, pharmaceutical substances and APIs, herbal extracts, concentrated herbal granules, and tea series products. The company also provides cosmetic series products, including moisture lotions, moisture creams, eye creams, and face washing foams; daily hygiene products, such as sanitary and carefree pads, honey-propolis soaps, and pollen soaps; and medical equipment, which include massage tappers, massage cushions, and circulation machines. It also exports its products to the United States, Russia, and countries in Europe, Africa, and rest of Asia. Tasly Pharmaceutical Group Co., Ltd. was founded in 1994 and is based in Tianjin, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||